Its potential benefit has been posited due to its effect on improving mitochondrial function and the benefit seen as a neuroprotective agent in other clinical situations such as ischemic stroke, neurodegenerative diseases, and chemotherapy-induced encephalopathy.13 The authors of one article posited 2-3mg/kg/day divided into three doses for 7-10 days for newly infected patients could be a reasonable dose for initial studies.14 Given one meta-analysis reported that 12-35% of patients with long COVID suffered from cognitive impairment (colloquially called brain fog) and another found elevated brain injury markers during the acute phase of COVID-19, potential treatment and management strategies are in demand.13,14,15 Currently there are some trials evaluating the use of methylene blue for COVID-19, though, results and outcomes are not yet available.16,17 Brain injury and traumatic brain injury continue to be significant sources of morbidity and mortality and effective treatment options for prevention of acute and long-term damage are needed

Split dosing becomes valuable when single dosing produces inconsistent results, when doses above 400mcg are needed, or when evening administration fits better into lifestyle patterns
Consumer confidence in these products diminishes due to concerns regarding their efficacy, potentially leading to decreased adoption rates
Researchers at institutions including the University of Gothenburg and Scripps Research Institute showed that semaglutide and similar compounds reduce voluntary alcohol intake, decrease nicotine self-administration, diminish cocaine-seeking behavior, and prevent relapse-like drinking after periods of abstinence